Nimbus Therapeutics builds highly selective small‑molecule medicines for oncology, immunology and metabolic diseases using an AI‑enhanced, structure‑based drug‑discovery platform. The company combines precision target selection, computational chemistry, and an integrated translational pipeline to design and advance selective inhibitors and activators from hit identification through preclinical and early clinical stages, partnering with large pharma to co‑develop these candidates.
Funding
$210M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
8OFounders
Product
Problem
Developing small‑molecule medicines for complex diseases such as oncology, immunology, and metabolic disorders requires highly selective compounds, extensive computational design, and efficient translation from discovery to clinic. Traditional drug‑discovery approaches often lack the precision and speed needed to generate novel, differentiated therapies for hard‑to‑target pathways.
Solution
Nimbus Therapeutics applies a precision‑focused small‑molecule platform that combines structure‑based computational chemistry, extensive target‑selection expertise, and selective chemistry to design highly selective inhibitors and activators. The company leverages proprietary AI‑enhanced modeling and structural biology to optimize potency, selectivity, and drug‑like properties early in discovery. Selected programs—such as a non‑covalent WRN helicase inhibitor for MSI‑high cancers, selective SIK2 inhibitors for inflammatory diseases, and isoform‑specific AMPK activators for metabolic disorders—are advanced through preclinical and clinical stages using a streamlined translational pipeline. Nimbus partners with large pharma (e.g., Eli Lilly, Takeda, Gilead) to co‑develop and commercialize these molecules, allowing rapid progression from computational design to human trials while maintaining rigorous selectivity and safety profiles.
Target Audience
Primary customers are pharmaceutical companies seeking highly selective small‑molecule candidates for oncology, immune‑mediated, and metabolic disease programs, as well as biotech investors interested in precision drug‑discovery platforms.
Features
- AI‑driven molecular property prediction and customized Amazon Nova models to accelerate hit identification.
- Structure‑based design pipeline integrating high‑resolution crystallography and computational chemistry for isoform‑selective kinase targeting.
- Non‑covalent inhibitor chemistry (e.g., WRN helicase inhibitor NDI‑219216) to achieve durable on‑target activity and broader therapeutic windows.
- Integrated translational medicine framework that moves candidates from discovery through IND filing into Phase 1/2 clinical trials.
- Strategic partnership model that licenses discovery assets to pharma partners while retaining lead optimization and early development responsibilities.
- Focus on exquisite selectivity across oncology, immunology, and metabolic indications to minimize off‑target toxicity.